[Inpharm Pharmaceuticals: 2026 First Half Loss of RMB 90.81 Million, Compared to RMB 129 Million in the Same Period Last Year] Inpharm Pharmaceuticals (07630.HK) announced that its revenue for the first half of 2026 was RMB 105 million, a year-on-year increase of 316.8%; the loss for the period was RMB 90.81 million, compared to a loss of RMB 129 million in the same period of 2025; the adjusted net loss was RMB 20.867 million, compared to a loss of RMB 55.841 million in the same period of 2025. The company entered into an exclusive collaboration with Pharmanovia, granting it exclusive rights to manufacture, develop and commercialize senaparib in Europe, the Middle East and North Africa, Australia and New Zealand, with upfront and milestone payments totaling up to €424 million.
